Edition:
India

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

84.17EUR
4:01pm IST
Change (% chg)

€0.23 (+0.27%)
Prev Close
€83.94
Open
€84.13
Day's High
€84.93
Day's Low
€84.00
Volume
759,728
Avg. Vol
2,513,785
52-wk High
€84.93
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.90
Market Cap(Mil.): €108,452.40
Shares Outstanding(Mil.): 1,292.02
Dividend: 2.96
Yield (%): 3.53

Financials

  SASY.PA Industry Sector
P/E (TTM): 24.78 29.24 29.98
EPS (TTM): 3.39 -- --
ROI: 5.02 13.55 13.08
ROE: 7.60 14.45 14.23

UPDATE 3-FDA approves Regeneron, Sanofi $37,000 per year eczema drug

March 28 The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies.

28 Mar 2017

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.

28 Mar 2017

BRIEF-Regeneron and Sanofi announce FDA approval of Dupixent

* Regeneron and Sanofi announce FDA approval of Dupixent® (Dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis

28 Mar 2017

BRIEF-U.S. list price for Sanofi, Regeneron's Dupixent $37,000

* Says U.S. list price of newly approved Dupixent atopic dermatitis drug $37,000 per patient per yearFurther company coverage: (Reporting by Ben Hirschler)

28 Mar 2017

FDA approves Regeneron, Sanofi eczema drug

March 28 The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's Dupixent for treatment of moderate to severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.

28 Mar 2017

BRIEF-Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi

* Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi

27 Mar 2017

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

23 Mar 2017

Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

LONDON, March 23 Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival.

23 Mar 2017

BRIEF-Sanofi genzyme extends its multiple myeloma journey partners program

* Sanofi genzyme extends its multiple myeloma journey partners program to cities nationwide to help improve patient outcomes through peer-to-peer education Source text for Eikon: Further company coverage:

22 Mar 2017

Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims

BOSTON Sanofi SA and Regeneron Pharmaceuticals Inc have filed a lawsuit seeking a court order declaring that their eczema drug Dupixent, awaiting a U.S. approval decision, does not infringe an Amgen Inc patent for a failed asthma treatment.

21 Mar 2017

More From Around the Web

Earnings vs. Estimates